Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma

Journal of Investigative Dermatology

Volumn 132, Issue 8, 2012, Pages 2042-2049

  Jones, Christine L ^a   Ferreira, Silvia ^a   McKenzie, Robert C T ^a   Tosi, Isabella ^b   Caesar, Jacqueline A ^a   Bagot, Martine ^c   Whittaker, Sean J ^a   Mitchell, Tracey J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; DINUCLEOTIDE; DIPEPTIDYL PEPTIDASE IV; MESSENGER RNA; PLS3 PROTEIN; POLYCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CELL POPULATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MUTATION; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN POLYMORPHISM; REGULATORY MECHANISM; SEZARY SYNDROME;

EID: 84863984448     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.106     Document Type: Article

References (36)

1. Agar NS, Wedgeworth E, Crichton S et al. (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28:4730-9
2. Bagot M, Moretta A, Sivori S et al. (2001) CD4 (+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood 97:1388-91
3. Booken N, Gratchev A, Utikal J et al. (2008) Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia 22:393-9
4. Bradford PT, Devesa SS, Anderson WF et al. (2009) Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 113:5064-73
5. Bruggemann M, van der Velden VH, Raff T et al. (2004) Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 18:709-19
6. Campbell JJ, Clark RA, Watanabe R et al. (2010) Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116:767-71
7. Capriotti E, Vonderheid EC, Thoburn CJ et al. (2008) Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. Leuk Lymphoma 49:1190-201
8. Chen H, Mocsai A, Zhang H et al. (2003) Role for plastin in host defense distinguishes integrin signaling from cell adhesion and spreading. Immunity 19:95-104
9. Contassot E, Kerl K, Roques S et al. (2008) Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood 111:4780-7
10. Drummond AJ, Ashton B, Buxton S et al. (2011) Geneious v5.4, Available from http://www.geneious.com/
11. Foran E, McWilliam P, Kelleher D et al. (2006) The leukocyte protein L-plastin induces proliferation, invasion and loss of E-cadherin expression in colon cancer cells. Int J Cancer 118:2098-104
12. Fraser-Andrews EA, Russell-Jones R, Woolford AJ et al. (2001) Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sezary syndrome. Cancer 92:1745-52
13. Haynes BF, Metzgar RS, Minna JD et al. (1981) Phenotypic characterization of cutaneous T-cell lymphoma. Use of monoclonal antibodies to compare with other malignant T cells. N Engl J Med 304:1319-23
14. Higuchi Y, Kita K, Nakanishi H et al. (1998) Search for genes involved in UVresistance in human cells by mRNA differential display: increased transcriptional expression of nucleophosmin and T-plastin genes in association with the resistance. Biochem Biophys Res Commun 248:597-602
15. Hisano T, Ono M, Nakayama M et al. (1996) Increased expression of T-plastin gene in cisplatin-resistant human cancer cells: identification by mRNA differential display. FEBS Lett 397:101-7
16. Ikeda H, Sasaki Y, Kobayashi T, et al., (2005) The role of T-fimbrin in the response to DNA damage: silencing of T-fimbrin by small interfering RNA sensitizes human liver cancer cells to DNA-damaging agents. Int J Oncol 27:933-40
17. Jones CL, Wain EM, Chu CC, et al., (2010) Downregulation of Fas gene expression in Sezary syndrome is associated with promoter hypermethylation. J Invest Dermatol 130:1116-25
18. Jones D, Dang NH, Duvic M, et al., (2001) Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 115:885-92
19. Kari L, Loboda A, Nebozhyn M et al. (2003) Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 197:1477-88
20. Klemke C-D, Brade J, Weckesser S et al. (2008) The diagnosis of Sézary syndrome on peripheral blood by flow cytometry requires the use of multiple markers. Br J Dermatol 159:871-80
21. Lin C, Lau A, Huynh T et al. (1999) Differential regulation of human T-plastin gene in leukocytes and non-leukocytes: identification of the promoter, enhancer, and CpG island. DNA Cell Biol 18:27-37
22. Lin CS, Park T, Chen ZP et al. (1993) Human plastin genes. Comparative gene structure, chromosome location, and differential expression in normal and neoplastic cells. J Biol Chem 268:2781-92
23. Nebozhyn M, Loboda A, Kari L et al. (2006) Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 107:3189-96
24. Oprea GE, Kröber S, McWhorter ML et al. (2008) Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320:524-7
25. Sasaki Y, Itoh F, Kobayashi T et al. (2002) Increased expression of T-fimbrin gene after DNA damage in CHO cells and inactivation of T-fimbrin by CpG methylation in human colorectal cancer cells. Int J Cancer 97:211-6
26. Steinhoff M, Schöpp S, Assaf C et al. (2009) Prevalence of genetically defined tumor cells in CD7 as well as CD26 positive and negative circulating T-cell subsets in Sézary syndrome. Leuk Res 33:88-99
27. Su MW, Dorocicz I, Dragowska WH et al. (2003) Aberrant expression of T-plastin in Sezary cells. Cancer Res 63:7122-7
28. Tang N, Gibson H, Germeroth T et al. (2010) T-plastin (PLS3) gene expression differentiates Sezary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. The British journal of dermatology 162:463-6
29. Tiemessen MM, Mitchell TJ, Hendry L et al. (2006) Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 126:2217-23
30. van der Velden VHJ, van Dongen JJM (2009) MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 538:115-50
31. van Doorn R, Dijkman R, Vermeer MH et al. (2004) Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sézary syndrome identified by gene expression analysis. Cancer Res 64:5578-86
32. van Krieken JHJM, Langerak AW, Macintyre EA et al. (2007) Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21:201-6
33. Wabnitz GH, Köcher T, Lohneis P et al. (2007) Costimulation induced phosphorylation of L-plastin facilitates surface transport of the T cell activation molecules CD69 and CD25. Eur J Immunol 37:649-62
34. Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-85
35. Willemze R, Kerl H, Sterry W et al. (1997) EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-71
36. Yoon JS, Newton SM, Wysocka M et al. (2008) IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome. J Invest Dermatol 128:473-80